CHA Bio & Diostech 
Welcome,         Profile    Billing    Logout  
 4 Products   0 Diseases   4 Products   7 Trials   56 News 


12»
  • ||||||||||  CordSTEM-DD (Enhanced umbilical cord adherent stem cell therapy) / CHA Bio & Diostech
    Trial completion:  Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain (clinicaltrials.gov) -  Aug 30, 2023   
    P1/2,  N=36, Completed, 
    Phase classification: P1b --> P1 | N=18 --> 42 | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025 Active, not recruiting --> Completed
  • ||||||||||  CordSTEM-DD (Enhanced umbilical cord adherent stem cell therapy) / CHA Bio & Diostech
    Enrollment closed, Phase classification, Trial completion date, Trial primary completion date:  Evaluation of Safety, Tolerability, and Efficacy of CordSTEM-DD in Patients With Chronic Low Back Pain (clinicaltrials.gov) -  Mar 22, 2023   
    P1/2,  N=36, Active, not recruiting, 
    The authors declare no conflict of interests to disclose. Not yet recruiting --> Active, not recruiting | Phase classification: P2 --> P1/2 | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Oct 2020 --> Apr 2023
  • ||||||||||  ASP7317 / Octapharma, Astellas
    Trial completion date, Trial primary completion date, Metastases:  A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD (clinicaltrials.gov) -  Nov 18, 2019   
    P1/2,  N=12, Active, not recruiting, 
    These results suggested that subretinal injection of hESC-derived RPE cells (60 and 120 × 10 cells/150 μL) in minipigs is well-tolerated and safe. Trial completion date: Apr 2016 --> Jun 2020 | Trial primary completion date: Feb 2016 --> Jun 2020
  • ||||||||||  ASP7317 / Octapharma, Astellas
    Trial completion, Trial completion date, Trial primary completion date:  Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients (clinicaltrials.gov) -  Nov 3, 2019   
    P1/2,  N=13, Completed, 
    Trial completion date: Apr 2016 --> Jun 2020 | Trial primary completion date: Feb 2016 --> Jun 2020 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019
  • ||||||||||  ASP7317 / Octapharma, Astellas
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD (clinicaltrials.gov) -  Oct 30, 2019   
    P1/2,  N=11, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jun 2019 | Trial primary completion date: Dec 2019 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2019 | Trial primary completion date: Dec 2019 --> Jul 2019
  • ||||||||||  CB-AC-02 / CHA Bio & Diostech
    Enrollment open, Trial completion date, Trial primary completion date:  Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease (clinicaltrials.gov) -  Sep 6, 2019   
    P1/2,  N=24, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2019 | Trial primary completion date: Dec 2019 --> Jul 2019 Not yet recruiting --> Recruiting | Trial completion date: Jun 2018 --> Dec 2021 | Trial primary completion date: Mar 2018 --> Dec 2021
  • ||||||||||  ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
    Review, Journal:  Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration. (Pubmed Central) -  Sep 5, 2019   
    Given that the technology is still at its infancy for human use, a new clinical regulatory path could aid in cell line validation through small cohort, adaptive clinical trials to accelerate product development toward commercialization. These strategic insights will be invaluable to help both academia and industry, collaboratively shorten the steep learning curve, and reduce large development expenditures spent on unnecessary lengthy clinical trials.
  • ||||||||||  ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
    Enrollment change, Trial withdrawal, Trial primary completion date:  Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) -  Jul 19, 2016   
    P1/2,  N=0, Withdrawn, 
    N=60 --> 8 | Suspended --> Terminated; Changes to the study design and the cell line N=12 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jul 2016
  • ||||||||||  ASP7317 / Octapharma, CHA Bio & Diostech, Astellas
    Enrollment open, Trial primary completion date:  Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration (clinicaltrials.gov) -  Feb 8, 2016   
    P1/2,  N=12, Recruiting, 
    Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Dec 2029 --> Aug 2029 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2017
  • ||||||||||  ASP7317 / Octapharma, Astellas
    Enrollment closed, Trial primary completion date:  Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) (clinicaltrials.gov) -  Feb 19, 2015   
    P1,  N=3, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Mar 2015